CAMZYOS® (mavacamten capsules) is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.1
Clinical Studies
EXPLORER-HCM
& VALOR-HCM
Safety Profile
EXPLORER-HCM
& VALOR-HCM
Dosing & Administration
Initiation, maintenance,
interruption, dose modification
Understanding Hypertrophic Cardiomyopathy (HCM)2
HCM is a common and frequently inherited disease that is characterized by left ventricular hypertrophy.
- Estimated prevalence: 1/500. While HCM is commonly inherited, relatively few patients are aware they have it.
- Impact of HCM: A major cause of morbidity and mortality, including exertional symptoms, heart failure, atrial fibrillation, stroke, and ventricular arrhythmias, potentially resulting in sudden cardiac arrest or death.
- Two forms of HCM: nonobstructive hypertrophic cardiomyopathy and obstructive hypertrophic cardiomyopathy, or oHCM.
- In oHCM, the thickened left ventricle can block blood flow out of the heart to the body. More than 60% of people with HCM will go on to develop obstructive HCM.
- Identification of oHCM is fundamental to the management of HCM.
2024 Clinical Practice Update from the Canadian Cardiovascular Society recommends the cardiac myosin inhibitor mavacamten as a second-line treatment option for adult patient with symptomatic oHCM.2
– Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient with Hypertrophic Cardiomyopathy 2024
Important Safety Information
CAMZYOS (mavacamten) is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
Consult the Product Monograph for important information about:
- Contraindications with concomitant use of strong CYP2C19 inhibitors; with concomitant use of moderate or strong inducers to both CYP2C19 and CYP3A4; during pregnancy; in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
- The most serious warnings and precautions regarding risk of heart failure.
- Other relevant warnings and precautions regarding heart failure due to systolic dysfunction; risk of heart failure or loss of response to CAMZYOS due to drug-drug interactions; safety of concomitant use with drugs that reduce cardiac contractility not fully established (expect additive negative inotropic effects; if initiated or dose of negative inotrope increased, monitor for systolic dysfunction/LVEF until stable doses/clinical response); not recommended with dual/triple therapy with negative inotropic agents (could increase risk of LV systolic dysfunction and heart failure symptoms); driving and operating machinery; teratogenic risk; females of reproductive potential; breastfeeding; severe renal impairment (eGFR <30 mL/min/1.73m2); not recommended in severe hepatic impairment (Child-Pugh Class C); potential need for CAMZYOS dose increase/titration with concomitant drugs; may be needed if concomitant moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor is discontinued after long-term use; monitor for new/worsening symptoms.
- Conditions of clinical use, adverse reactions, drug interactions and dosing.
The Product Monograph is also available by calling 1-866-463-6267.
† Please see the Product Monograph for complete dosing and administration instructions.
‡ For patients in maintenance phase and on a stable individualized dose of CAMZYOS.1.
References: 1. CAMZYOS (mavacamten capsules) Product Monograph. Bristol Myers Squibb Canada. 2. Crean AM, et al. Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient with Hypertrophic Cardiomyopathy. Can J Cardiol 2024;1-21.; 3. Prix Galien Canada – Innovative Product Award. https://hrf-frs.com/news/bristol-myers-squibb-canada-wins-the-2024-prix-galien-innovative-product-award/. Accessed November 5, 2025.